SARS-CoV-2 causing the worldwide pandemic has changed people's life in multiple aspects
dramatically since it's first identified in Wuhan, China at the end of 2019. While the numbers …

ABSTRACT Introduction Neutralizing antibodies (NAbs) that target key domains of the spike
protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have …

The emergence of the highly transmissible B. 1.1. 529 Omicron variant of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …

The global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic
requires effective therapies against coronavirus disease 2019 (COVID-19), and neutralizing …

In the absence of virus-targeting small-molecule drugs approved for the treatment and
prevention of COVID-19, broadening the repertoire of potent SARS-CoV-2-neutralizing …

SARS-CoV-2 can mutate to evade immunity, with consequences for the efficacy of emerging
vaccines and antibody therapeutics. Herein we demonstrate that the immunodominant …

Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines show
protective efficacy, which is most likely mediated by neutralizing antibodies recognizing the …

The successive emergences and accelerating spread of novel severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) lineages and evolved resistance to some ongoing …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes the
disease COVID-19 can lead to serious symptoms, such as severe pneumonia, in the elderly …

Effective clinical intervention strategies for coronavirus disease 2019 (COVID-19) are
urgently needed. Although several clinical trials have evaluated use of convalescent plasma …